Sarizotan low dose

Small molecule

NNewron Pharmaceuticals SPA

Sarizotan low dose is one of 26 small molecule programs targeting Rett syndrome. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rett SyndromeActive, not recruiting

Rett SyndromePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Rett Syndrome

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Approved

—2

Norpramin

VValidus Pharmaceuticals

Risperdal

GWP42003-P

2 5

Donepezil Hydrochloride

Eisai

Phase 3

1 6

Robitussin

Pfizer

Phase 2

4 7

Copaxone

Teva

Phase 2

2 8

Dojolvi

Ultragenyx

Phase 2

1 9

Ketalar

AAultman Health Foundation

Phase 2

1 10

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rett syndrome1 trial

Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Terminated·NNewron Pharmaceuticals SPA·Phase 2/3·NCT02790034·129 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sarizotan low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sarizotan low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sarizotan low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Newron Pharmaceuticals SPA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: NNewron Pharmaceuticals SPA

Sarizotan low dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rett syndrome1 trial

References

Drug Info

Quick Facts

Related News